Ryman Healthcare Valuation
Is RHCG.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RHCG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RHCG.F ($2.61) is trading below our estimate of fair value ($4.63)
Significantly Below Fair Value: RHCG.F is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RHCG.F?
Key metric: As RHCG.F is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is RHCG.F's PS Ratio? | |
|---|---|
| PS Ratio | 5x |
| Sales | NZ$687.56m |
| Market Cap | NZ$3.43b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.7x |
| Enterprise Value/EBITDA | 375.7x |
| PEG Ratio | 31.7x |
Price to Sales Ratio vs Peers
How does RHCG.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
NHC National HealthCare | 1.6x | n/a | US$1.9b |
USPH U.S. Physical Therapy | 2.3x | 8.9% | US$1.4b |
ARDT Ardent Health Partners | 0.4x | 6.8% | US$2.3b |
CON Concentra Group Holdings Parent | 1.5x | 5.6% | US$2.7b |
RHCG.F Ryman Healthcare | 5x | 9.0% | US$3.4b |
Price-To-Sales vs Peers: RHCG.F is expensive based on its Price-To-Sales Ratio (5x) compared to the peer average (1.4x).
Price to Sales Ratio vs Industry
How does RHCG.F's PS Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: RHCG.F is expensive based on its Price-To-Sales Ratio (5x) compared to the US Healthcare industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is RHCG.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate RHCG.F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$2.61 | US$3.67 +40.5% | 10.9% | US$4.11 | US$2.95 | n/a | 5 |
| Nov ’25 | US$3.10 | US$3.87 +25.0% | 10.9% | US$4.34 | US$3.12 | n/a | 5 |
| Oct ’25 | n/a | US$3.87 0% | 10.9% | US$4.34 | US$3.12 | n/a | 5 |
| Sep ’25 | n/a | US$3.65 0% | 13.3% | US$4.20 | US$2.80 | n/a | 5 |
| Aug ’25 | n/a | US$3.62 0% | 13.3% | US$4.17 | US$2.78 | n/a | 5 |
| Jul ’25 | n/a | US$3.68 0% | 18.2% | US$4.44 | US$2.47 | n/a | 5 |
| Jun ’25 | US$2.22 | US$3.70 +66.7% | 18.1% | US$4.44 | US$2.47 | n/a | 5 |
| May ’25 | n/a | US$4.42 0% | 19.3% | US$5.70 | US$3.14 | n/a | 5 |
| Apr ’25 | n/a | US$4.63 0% | 18.9% | US$5.92 | US$3.26 | n/a | 5 |
| Mar ’25 | n/a | US$4.63 0% | 18.9% | US$5.92 | US$3.26 | n/a | 5 |
| Feb ’25 | n/a | US$4.85 0% | 17.6% | US$5.91 | US$3.34 | n/a | 5 |
| Jan ’25 | US$3.62 | US$4.85 +33.8% | 17.6% | US$5.91 | US$3.34 | n/a | 5 |
| Dec ’24 | n/a | US$4.85 0% | 17.6% | US$5.91 | US$3.34 | n/a | 5 |
| Nov ’24 | n/a | US$4.69 0% | 18.1% | US$5.82 | US$3.20 | US$3.10 | 5 |
| Oct ’24 | n/a | US$4.68 0% | 18.4% | US$5.93 | US$3.26 | n/a | 5 |
| Sep ’24 | n/a | US$4.86 0% | 18.4% | US$6.17 | US$3.39 | n/a | 5 |
| Aug ’24 | n/a | US$4.86 0% | 18.4% | US$6.17 | US$3.39 | n/a | 5 |
| Jul ’24 | US$3.95 | US$4.86 +23.1% | 18.4% | US$6.17 | US$3.39 | n/a | 5 |
| Jun ’24 | n/a | US$4.74 0% | 19.0% | US$6.07 | US$3.34 | US$2.22 | 5 |
| May ’24 | n/a | US$4.60 0% | 22.3% | US$6.14 | US$3.00 | n/a | 5 |
| Apr ’24 | n/a | US$5.02 0% | 15.1% | US$6.19 | US$4.07 | n/a | 4 |
| Mar ’24 | US$3.40 | US$5.42 +59.5% | 10.8% | US$6.24 | US$4.90 | n/a | 3 |
| Feb ’24 | n/a | US$6.51 0% | 27.0% | US$9.27 | US$4.80 | n/a | 5 |
| Jan ’24 | US$3.50 | US$6.51 +85.9% | 27.0% | US$9.27 | US$4.80 | US$3.62 | 5 |
| Dec ’23 | n/a | US$6.51 0% | 27.0% | US$9.27 | US$4.80 | n/a | 5 |
| Nov ’23 | US$4.66 | US$6.41 +37.7% | 23.6% | US$8.56 | US$4.75 | n/a | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Lantheus Holdings
US$6.0b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$87.32
7D
8.0%
1Y
27.8%
Centene
US$29.8b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$60.35
7D
2.8%
1Y
-18.7%
electroCore
US$64.1m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$9.92
7D
-27.1%
1Y
80.4%